공지
- [ 2024-06-28 ] 2024년 하반기(7월) 유전자검사기관 종사자 교육 안내
- [ 2024-06-12 ] 2024년 하반기 DTC 유전자검사기관 검사역량인증 사업 설명회 개...
- [ 2024-06-11 ] 2024 연명의료결정제도 수기·영상 공모전 안내
- [ 2024-06-05 ] [제63회 콜로키움] (구)독일 형법상 '업무상 자살 지원' 금지의 ...
- [ 2024-06-05 ] 2024년 한국간호윤리학회 세미나 개최 안내(6/22(토))
관련 논문
*정책원 미소장 자료이며 관련 논문 소개 게시판입니다. 게시물 관련링크를 눌러 소속기관에서 열람가능한지 확인해주시기 바랍니다.
lib@nibp.kr
글 수 869
| 발행년 : | 2018 |
|---|---|
| 구분 : | 학위논문 |
| 학술지명 : | 학위논문(석사)-- 忠南大學校 大學院: 생명과학과 |
| 관련링크 : | http://www.riss.kr/link?id=T14771222 |
빅데이터 분석을 통한 뇌전증 치료제 연구동향에 관한 연구
- 저자[authors] 권상조
- 발행사항 대전: 忠南大學校 大學院, 2018
- 형태사항[Description] 57 p.; 26 cm.
- 일반주기명[Note] 충남대학교 논문은 저작권에 의해 보호받습니다.<br>지도교수: 김철희<br>참고문헌 : p. 49-54.
- 학위논문사항[Dissertation] 학위논문(석사)-- 忠南大學校 大學院: 생명과학과 2018. 2
- DDC[DDC] 579 22
- 발행국(발행지)[Country] 대전
- 출판년[Publication Year] 2018
- 소장기관[Holding] 충남대학교 도서관 (225009)
초록[abstracts]
Epilepsy is one of the major neurological diseases characterized by recurrent seizures, and is highly prevalent in elderly and children. The research on the onset mechanism of epilepsy is still in progress. This study was carried out to investigate the research trend of anti-epileptic drug through big data analysis. The research subjects were patents filed from 1996 to 2015, and about 6,506 cases were analyzed. Quantitative and qualitative analysis were carried out based on the information described in the patent documents. As a result, the number of patent applications related to anti-epileptic drug had been increased from 1996 to 2007, but it had gradually decreased since 2007, and more than 50% of all patent applications were filed in the US. Patent applications by pharmaceutical companies based on the US and Europe, including Pfizer, Neurosearch A/S and Sanofi S.A. were active, and the top five applicants showed a high level of patent activity in four major countries (Korea, Japan, Europe, and the United States). On the other hand, patent application activity of Korea pharmaceutical companies was relatively low. And this study revealed that the US is leading the development of technology related to anti-epileptic drug, and research activities centering on pharmaceutical companies are being actively carried out. PFS is a market reach index used in patent analysis. In European countries, PFS are relatively high and in Korea, PFS is lower than the average. And then through the patent portfolio analysis, this study confirmed that the technology position of the US patent was at the maturity stage, and the technology positions of Korea, Japan, and European patents, were at a declining stage. In conclusion, the technology position of the anti-epileptic drug is located at the maturity stage, and research activity and market dominance are dominated by multinational pharmaceutical companies based on the US and Europe. Korea's research activity and market reach index are poor, and the proportion of patent activities of public institutions and universities is higher than other countries. As a result of selecting and analyzing key patents, multinational pharmaceutical companies had the key patent rights and key patents were cited by other pharmaceutical companies. In order to enter the epilepsy drug market, patent avoidance design is expected to be necessary. And the efficacy of retigabine was clearly confirmed in an experiment using zc4h2 knock-out zebrafish screening system. zc4h2 knock-out zebrafish is very useful for testing or screening anticonvulsant compounds. In this study, we could confirm the level of domestic technology and the technology gap between domestic and foreign countries. When considering domestic research conditions, the joint research by companies, public institutions and universities for the development of anti-epileptic drug is expected to be a good opportunity for domestic technology to penetrate the epilepsy drug market, where generic drug has entered in earnest.
(†04522) 서울 특별시 중구 남대문로 113 DB다동빌딩 5층
TEL : 02-737-8970 (기획운영팀)
Copyright (c)KONIBP All Right Reserved.
Copyright (c)KONIBP All Right Reserved.
2sisstore
